OBJECTIVES:
To assess the clinical characteristics of patients with RA receiving their first biologic in 5EU. METHODS: A multi-country multi-center medical chart-review study of RA patients was conducted among physicians (rheumatologists:97%) in hospitals and private practices to collect de-identified data on patients who were recently treated with a biologic as part of usual care. Physicians were screened for duration of practice (3-30 yrs) and patient volume (incl. >2RA biologic patients/week) and recruited from a large panel to be geographically representative in each country. Eligible patient charts (>5) were randomly selected from a sample of prospective patients visiting each center/practice during the screening period. Physicians abstracted patient diagnosis, treatment patterns/dynamics and patient symptomatology/disease status. RESULTS: In 1Q2012, 2208 eligible RA patient charts were abstracted; 1562 (71%) patients were on their first biologic (mean-age:50.7yrs, female:71%). Geographic distribution of patients were -UK:19%, Germany:18%, France:22%, Italy:23%, Spain:18%. Time-to-1 st biologic from diagnosis (range:31mo (Italy)-52mo (France)) and time-on-current biologic (range:17month (Italy)-27month (France)) differed within 5EU. The top-3 reasons for biologic treatment initiation were consistent across 5EU ('mechanism of action', 'improve signs/symptoms', 'prevent structural damage'), whereas the next 2 reasons differed (UK/Germany: 'disease worsened' & 'positive personal experience'; France: 'inhibits disease' & 'mode of administration'; Italy: 'frequency of administration' & 'positive personal experience'; Spain: 'positive personal experience' & 'inhibits disease progression'). Key lab measures documented were: ESR (range:20.8mm/h (France)-29.1mm/h (Italy)) and CRP (range:6.9mg/dl (Spain)-15.0mg/dl (UK)). Current disease severity per physician-judgment (mild:moderate:severe) in 5EU were: UK-58%:29%:13%, Germany-50%:44%:7%, France-39%:48%:12%, Italy-47%:49%:4%, Spain-59%:36%:5%. Among patients with available data, current HAQ (range: 0.7(Spain)-1.5(Germany)), DAS28 (range:3.0(Spain)-3.8(Germany)), 100mmVAS (range:23.3(France)-34.8(Italy)) and Total Sharp (range:0.9(France)-(3.6(Germany)) differed within 5EU. CONCLUSIONS: Among RA patients receiving their first biologic, disease severity differed within 5EU, with patients in Germany with relatively higher burden. Impact of specific biologic treatments on the observed patterns warrants further scrutiny. 
PMS62 A MULTI-COUNTRY PHYSICIAN SURVEY ON PATIENT ELIGIBILITY AND USE OF BIOLOGICS IN RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA) IN EUROPEAN UNION (EU)

OBJECTIVES:
To assess physician assessment of patient eligibility and eventual use of biologics in RA, AS and PsA in EU. METHODS: A multi-country physician survey was conducted in 5EU (UK, Germany, Spain, France, Italy) in RA, AS and PsA. Physicians were screened for experience (3-30yrs) and biologic patient volume (>2RA biologic patients/week, >5AS biologic patients/month, >5PsA biologic patients/month) and recruited from a large physician-panel to be geographically representative in each country. Practice characteristics, patientvolume, physician perceptions and practice patterns were assessed; physicians' target patient population was grouped into 2 categories, based on physician input: Group1 -patients perceived to be eligible for biologics, Group2 -patients who ended up receiving biologics within Group1. Summary statistics across 5EU are reported. RESULTS: In the first quarter 2012, 434 physicians (rheumatologists: 97%; internist: 3%) participated in the study. Mean age: 45yrs; female: 35%; exclusively hospital-based practice:71%. Geographic distribution of physicians was: UK-18%, Germany-19%, Spain-19%, France-22%, Italy-22%. Patient volume per physician was: total-1065, RA-207, AS-80, PsA-88. Average frequency of patient encounters were: RA-11wks, AS-12wks, PsA-11wks. Physician global assessment of patient disease severity were (average across patients): RA mild: 35%/moderate: 41%/severe: 23%, AS -mild: 37%/moderate: 39%/severe: 24% and PsA-mild: 37%/moderate:39%/severe: 24%. Physician assessment of patient eligibility and use of biologics were: within RA-mild-patients -Group1: 18%/Group2: 10%, within RA-moderate-patients-Group1: 45%/Group2: 33%, within RA-severe-patients-Group1: 76%/Group2: 66%; within AS-mild-patientsGroup1: 20%/Group2: 11%, within AS-moderate-patients-Group1: 48%/Group2: 37%, within AS-severe-patients-Group1: 77%/Group2: 69%; within PsA-mildpatients-Group1: 22%/Group2: 12%, within PsA-moderate-patients-Group1: 51%/Group2: 37%, within PsA-severe-patients-Group1: 76%/Group2: 66%; Among patients who received biologics, Enbrel, Humira and Remicade were the top-3 prescribed medications across RA/AS/PsA. CONCLUSIONS: Across the markets, approximately one-tenth of biologic eligible patients (per physician perception) within corresponding disease severity groups did not end up receiving a biologic, across RA/AS/PsA, with the discordance slightly more pronounced within moderate patients. Reasons behind these patterns and the impact on subsequent patient outcomes warrants further scrutiny. 
PMS63 VALUE-BASED INSURANCE DESIGN INFORMED BY GOVERNMENT RESEARCH: A CASE STUDY OF OSTEOPOROSIS FRACTURES
OBJECTIVES:
To use a mixed-treatment meta-analysis and simulation model to estimate fracture reductions and cost savings achievable from switching osteoporosis patients to more efficacious treatments in a large health plan.
METHODS:
We populated the Bayesian mixed-treatment meta-analysis using studies identified within a recent AHRQ systematic review of anti-osteoporosis agents. We considered anti-osteoporosis drugs included in a health plan's pharmacy benefit, i.e., alendronate, ibandronate, raloxifene, risedronate, and teriparatide and these drugs' effect upon the clinical endpoints of vertebral, hip, and other fractures. We used the results of the meta-analysis to populate a stochastic simulation model to examine a cohort of 13,337 individuals with an osteoporosis diagnosis in a large private health plan. We compared the expected number of vertebral, hip, and other fractures and cost of care (drug and hospitalization costs) between the existing distribution of treatments as identified by claims data and a distribution optimized in accordance with the mixed-treatment meta-analysis. We obtained drugs costs from claims data and hospitalization costs from the literature. RESULTS: Results from the mixedtreatment meta-analysis suggest that ibandronate and raloxifene are associated with worse outcomes than alendronate, risedronate, and teriparatide across the considered endpoints. Therefore, our simulation switched patients from ibandronate and raloxifene and increased the proportion of patients treated with alendronate, risedronate, and teriparatide. Results suggest a substantial reduction in clinical events and economic savings (18% reduction of clinical events, including a 30% reduction in new hip fractures, a 5% in vertebral fractures, and a 9% reduction in other fractures). We estimate total economic savings to the health plan of over $750 per covered patient, over $10 million in aggregate. CONCLUSIONS: Opportunities to leverage existing research can help inform value-based pharmacy benefit design. The optimized allocation of treatments can increase the health of beneficiaries while providing savings for payers.
PMS64 HIP AND KNEE ARTHROPLASTY: HOW MUCH THESE PROCEDURES IMPACTS IN THE BRAZILIAN HEALTH CARE EXPENDITURES?
Araújo 
OBJECTIVES:
The number of hip and knee arthroplasty has been growing steadily over the last decade because they are effective procedures that improve quality of life and functional capacity and decrease pain. They have been proven to be cost-effective procedures in different countries. The objective of this study is to quantify the number and expenditure with these procedures in Brazil. METHODS: We used for the public health care system data from the hospital information system (SIH/SUS) database and for the private health care data from the BI2iM database that has 5 million lives. We used the codes for each of these two procedures as search base. All values are in 2010 Brazilian reais (US$1.00=R$ 2.00). RESULTS: A total of 20,116 hip and 6,320 knee arthroplasties were performed in the public system and 20,212 hip and 16,206 knee arthroplasties were performed in the private health system. The total expenditure to the Brazilian health system generated by these procedures was R$ 584,6 millions. For hip procedures the expenses for the public and private systems were respectively R$ 60,8 millions and R$ 280 millions. For knee procedures the expenses for the public and private systems were R$ 15,3 millions and R$ 228, 5 millions. CONCLUSIONS: Hip and knee arthroplasties represents an important amount of investment for both public and private health care systems in Brazil. These are initial data to be used in future studies to determine the costeffectiveness and budgetary impact of different therapies linked to this procedure in Brazil. 
PMS65
OBJECTIVES:
Osteoarthritis is characterized by joint pain and mobility impairment associated with the gradual wearing of cartilage. Osteoarthritis poses a substantial and increasing burden on society as a result of impaired health-related quality of life and the socio-economic impact. In Russia, there are no solid estimates of the magnitude of the condition. This study is aimed to assess co-morbidity, quality of life (QOL), work/productivity loss, and medical resource utilization in Russian urban adults with osteoarthritis. METHODS: Patients' self-reported data were collected from 2011 National Health and Wellness Survey (NHWS). Survey samples represented major urban areas in Russia. QOL was measured by the physical component score (PCS) and mental component score (MCS) of the Short Form-12 (SF-12). Loss of work productivity was measured by the Work Productivity and Activity Impairment instrument. Medical resource utilization was measured by health care provider, ambulance request and hospitalization in the past 6 months. RESULTS: Of the 10,039 adult respondents, 733 (7.3%) were diagnosed with osteoporosis (2.2% not diagnosed with osteoarthritis and 88.1% have not experienced arthritis at all). Average age of patients diagnosed with osteoarthritis was 54.1 years. Diagnosed osteoarthritis group reported more co-morbidities (sleep difficulties 51%, high blood pressure 46%, pain 44%, insomnia 37%, arrhythmia 30%, high cholesterol 21%), lower mean scores of PCS (40.4 vs.47.3) and similar MCS (43.3 vs.43.8). More patients visited health care providers (83% vs.70%), and a higher percentage were hospitalized (17% vs. 9%) over the past 6 months compared to those not experiencing arthritis. Furthermore, osteoarthritis group reported 37.6% impairment in daily activity compared to 25.3% of those not experiencing arthritis. All mentioned differences were statistically significant (p<0.05). CONCLUSIONS: From Russian NHWS results, patients diagnosed with osteoarthritis suffer from impairment in QOL, work/productivity loss and more co-morbidities. Findings indicate there is still an unmet medical need in Russian osteoarthritis patients. 
PMS66 PAYER COVERAGE ANALYSIS OF CHONDROITIN SULFATE WITH GLUCOSAMINE FOR OSTEOARTHRITIS IN THE UNITED STATES
OBJECTIVES:
American patient consumers spend in excess of $1B annually on drugs to treat Arthritis. Osteoarthritis is a condition that can lead to Rheumatoid Arthritis. This study looks at how public and private payers in the United States might cover the use of Chondroitin Sulfate with Glucosamine for treating Osteoarthritis. METHODS: Published coverage policies for products used to treat Osteoarthritis (OA) were gathered and analysed, along with primary data developed through payer interviews. Interviewees selected included pharmacy directors at private payers and those who administered Medicare Part D plans (N=3). RESULTS: Findings show that payers would provide coverage of chondroitin sulfate with glucosamine for Osteoarthritis if: a) The cost were less than $100/month; b) The Centers for Medicare and Medicaid Services (CMS) provides coverage; c) Data demonstrated improved outcomes over treatments like omega-3-acid ethyl esters and niacin tablet, film-coated extended-release. Payers also indicated that they would afford chondroitin sulfate with glucosamine with Tier 2 formulary status, similar to that of omega-3-acid ethyl esters and niacin tablet, film-coated extended-release. CONCLUSIONS: Based on our research, we believe US Medicare Part D plans and private payers would cover chondroitin sulfate and chondroitin sulfate with glucosamine products provided there is clinical data demonstrating its efficacy in OA patients, and assuming that CMS would approve this product as an exception to its coverage policy for nutritional supplements. All payers expressed that currently there are limited or no treatment options for OA patients, implying that a product that shows some statistically significant benefit will be covered and reimbursed by them. If clinical data shows efficacy in some or all OA patients, we believe the market could provide for a significant price premium as compared to current OTC products. 
PMS67 FREQUENCY OF OUTPATIENT PHYSIOTHERAPY SERVICES IN TRAUMA DISEASES IN HUNGARY
OBJECTIVES:
The aim of our study is to assess the amount, frequency, and the health insurance expenses related to trauma diseases within out-patient care.
METHODS:
The data come from the financial data base of the National Health Insurance Fund Administration (in Hungarian: OEP) involving the year of 2009. The health procedure activity list was provided by the rulebook on the application of the activity code list in out-patient care. The trauma syndromes were reported in diagnosis code S00-S99. RESULTS: Trauma injuries account for 3471657 cases in the annual number of the physiotherapy-related activities (32318413 cases) showing an approximately 10.5% prevalence. The 20 most frequent treatments accounts for 86.3 % (2997907) of total services. The following top-10 medical procedure were responsible for 68.14% (2365569) of total activities: individual training (10.95 %), muscle strengthening exercise (9.0 %), stretching of contractura (8.13), mobilization of joints (7.24 %), exercises against resistance (7.02 %), training for circulation improvement (6.4 %), exercise to prevention of cardiovascular complications (6.05%), passive movement of physical landscape (4.94%), gymnasztics (4.22%), Parts of the body per individual physiotherapy (4.17). Physiotherapy out-patient care for trauma patients were 3.4 million cases with 901 million Hungarian Forint (3,2 million Euro) health insurance subsidy CONCLUSIONS: The 20 most commonly used activities out of 151 with 86,3% incidence shows a varied content. The list of the 20 most frequent types of services reflects to the demand for the combination of active and passive exercises, providing an active, functional training for injured patients. 
PMS68 AGE AND GENDER DISTRIBUTION OF OUTPATIENT CARE PHYSIOTHERAPY SERVICES FOR TRAUMATIC INJURIES IN HUNGARY
OBJECTIVES:
The aim of our study is to assess the utilization of out-patient care physiotherapy services related to trauma diseases according to age and gender. METHODS: The data come from the financial data base of the National Health Insurance Fund Administration (in Hungarian: OEP) involving the year of 2009. The OENO activity list was provided by the rulebook on the application of the activity code list in out-patient care. The trauma syndromes were reported according to WHO ICD diagnosis code S00-S99. We analyzed the medical procedures according to the Hungarian versions of the WHO "International Classification of Procedures in Medicine". We analyzed the utilization of physiotherapy services according to age and gender. RESULTS: Trauma injuries account for 3471657 cases within the annual number of the physiotherapyrelated activities (32318413 cases) showing an approximately 10.5% prevalence. Increasing with age, the number physiotherapy procedures per 10000 population is on the rise with a national mean value of 3386. There is no significant difference between the mean values in both genders (females=3272, males=3349). The highest number of physiotherapy treatment is provided for the men patients in the age group 55 to 59 (4525) followed by age groups of 35 to 45 with 4225 and 4272 cases. The oldest women age group show the highest value in this gender (7664), followed by age groups of 75 to 85 with 6057 and 6041 cases per 10000. The number of injury-related cases are higher in men until 49 years of age, but over 50 years of age is higher for women. CONCLUSIONS: In case of the traumatic injuries, the highest demand of the outpatient care physiotherapy services occurred older injured patients. The claim indicators were significantly higher for men and women over 50 years of age. 
PMS69 DISTRIBUTION OUTPATIENT PHYSIOTHERAPY SERVICES IN THE DIFFERENT TRAUMA DISEASES ACCORDING TO MAJOR BODY PARTS IN HUNGARY
OBJECTIVES:
The aim of our study is to assess amount and frequency of the physiotherapy services in the different regions of trauma diseases within outpatient care. METHODS: The data come from the financial data base of the National Health Insurance Fund Administration (in Hungarian: OEP) involving the year of 2009. The OENO activity list was provided by the rulebook on the application of the activity code list in out-patient care. The trauma syndromes were reported according to WHO ICD diagnosis code S00-S99. We analyzed the medical procedures according to the Hungarian versions of the WHO "International Classification of Procedures in Medicine". The distribution of physiotherapy procedures were calculated accroding to major body parts. RESULTS: The total number of the 151 different types WHO-classified physiotherapy procedures was 32318413 in the year of 2009; and 3471657 (10.5%) of them related to trauma care with the ICD code group S00-S99. The amount and frequency of the physiotherapy services are in the 10 different trauma regions are the following: injuries of the head 57 615 (1.66%), neck 27683 (0.80%), thorax 67720 (1.95%), abdomen, lower back, lumbar spine and pelvis 73857 (2.13%), shoulder and upper arm 697896 (20.10%), elbow and forearm 656537 (18.91%), wrist and hand 466360 (13.43%), hip and thigh 353260 (10.18%), knee and lower leg 794326 (22.88%), ankle and foot 276403 (7.96%). CONCLUSIONS: The annual number of extremity injuries is the highest, while that of the torso, neck and head injuries is the smallest. Most cases treated in the region of the knee and leg, followed by the region of the upper extremity. In case of capacity planning for diagnostic and therapeutic procedures, these findings should be considered.
